GENDER, VIABILITY AND/OR DEVELOPMENTAL STAGE DETERMINATION OF AVIAN EMBRYOS IN OVO
    2.
    发明申请
    GENDER, VIABILITY AND/OR DEVELOPMENTAL STAGE DETERMINATION OF AVIAN EMBRYOS IN OVO 审中-公开
    性别,可行性和/或发展阶段确定海洋中的AVIAN EMBRYOS

    公开(公告)号:US20150260704A1

    公开(公告)日:2015-09-17

    申请号:US14418506

    申请日:2013-07-30

    申请人: IN OVO B.V.

    IPC分类号: G01N33/483 G01N33/50 C12N7/00

    摘要: The present invention relates to a process for the non-destructive determination of gender, developmental stage and/or viability of an avian embryo in an egg, comprising (a) detecting at least a first developmental marker compound selected from sugars and/or amino acids, precursors and metabolites thereof in an egg at a time period of from the beginning of the incubation of the egg until the hatching; (b) measuring the amount of the at least first detected developmental marker compound, and (c) comparing the amount to a base line established for male and female, developmental stage of the embryo, and/or alive and deceased or non-developed embryo, to determine whether the embryo is viable, male and/or female, and/or the developmental stage of the embryo.

    摘要翻译: 本发明涉及一种用于非蛋白质测定卵中禽类胚胎的性别,发育阶段和/或生存力的方法,其包括(a)至少检测选自糖和/或氨基酸的第一发育标记化合物 ,蛋的前体和代谢物在卵孵化开始到孵化的时间段; (b)测量所述至少第一检测到的发育标记化合物的量,和(c)将所述量与为男性和女性建立的基线,胚胎发育阶段和/或活的和已故的或未开发的胚胎进行比较 ,以确定胚胎是否存活,男性和/或女性,和/或胚胎的发育阶段。

    BLOOD LACTATE RANGE TARGETS AND NUTRITIONAL FORMULATIONS AND PROTOCOLS TO SUPPORT PATIENTS
    7.
    发明申请
    BLOOD LACTATE RANGE TARGETS AND NUTRITIONAL FORMULATIONS AND PROTOCOLS TO SUPPORT PATIENTS 审中-公开
    血液标准范围目标和营养配方和协议支持患者

    公开(公告)号:US20160066609A1

    公开(公告)日:2016-03-10

    申请号:US14941197

    申请日:2015-11-13

    摘要: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

    摘要翻译: 公开了用于估计患者的代谢状态或通量的系统,技术和方法,例如身体能量状态(“BES”)。 BES提供了对患者的营养需求的深入了解,从而允许对患者进行一种精细的血糖控制。 本发明公开了用于估计部分糖异生的系统和方法。 本发明还公开了用于估计和靶向患者血液乳酸盐浓度的系统和方法,既作为靶标本身,又作为评估和靶向患者分数糖异生葡萄糖产生的中间步骤。 还公开了营养支持方法和制剂。 本发明适用于任何类型的患者,包括受伤的患者,例如创伤性脑损伤,生病或有其他压力代谢系统的病症。